Midsummer Capital

Kwanji Ltd operates a foreign exchange comparison platform that enables businesses to access and compare foreign exchange rates from regulated brokers and banks. Founded in 2011 and based in London, the company provides a user-friendly service that allows importers, exporters, and treasury sectors to quickly evaluate multiple FX quotes, facilitating efficient global transactions. Kwanji's platform supports instant transactions and offers future payment options, helping users save time and money by avoiding overcharges. By bridging both emerging and traditional markets, Kwanji empowers businesses to trade more effectively on a global scale.

Kwanji Ltd operates a foreign exchange comparison platform that enables businesses to access and compare foreign exchange rates from regulated brokers and banks. Founded in 2011 and based in London, the company provides a user-friendly service that allows importers, exporters, and treasury sectors to quickly evaluate multiple FX quotes, facilitating efficient global transactions. Kwanji's platform supports instant transactions and offers future payment options, helping users save time and money by avoiding overcharges. By bridging both emerging and traditional markets, Kwanji empowers businesses to trade more effectively on a global scale.

Sevion Therapeutics is a biopharmaceutical company focused on discovering, developing, and acquiring innovative therapies for cancer and immunological diseases. The company advances a pipeline of proprietary and partnered product candidates utilizing its unique antibody technology platforms. This pipeline aims to create biologic therapies targeting previously inaccessible areas, including multispanning membrane proteins and ion channels involved in various diseases. Additionally, Sevion has developed a pioneering protein nanocage system designed for the targeted delivery of nucleic acids and other therapeutic payloads to specific cells. Through its research and development efforts, Sevion is dedicated to addressing critical therapeutic needs in the treatment of cancer and inflammatory diseases.

CEL-SCI Corporation is a biotechnology company based in Vienna, Virginia, that focuses on the research and development of immunotherapy products for cancer and infectious diseases. Its leading investigational therapy, Multikine, is currently undergoing phase III clinical trials for treating head and neck cancer. Additionally, CEL-SCI has developed a proprietary platform known as the Ligand Epitope Antigen Presentation System (LEAPS), which aims to enhance the human immune response against various health issues, including bacterial, viral, and parasitic infections, as well as autoimmune diseases and cancer. The company is also exploring other product candidates, such as LEAPS-H1N1-DC for influenza, CEL-2000 and CEL-4000 for rheumatoid arthritis, and LEAPS COV-19 for COVID-19. CEL-SCI collaborates with the University of Georgia’s Center for Vaccines and Immunology to advance its COVID-19 immunotherapy efforts. Founded in 1983, CEL-SCI continues to innovate in the biopharmaceutical sector.